L3VLUP
ProSign in

GMAB in the 13F filings

Genmab A S · CUSIP 372303206

Sector · Pharmaceuticals and biotechnologyTheme · Healthcare: biopharma and medtech· L3VLUP-definedTheme · Pharmaceutical preparations
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Quarter end
30 Sep 2023
the date the book describes
Filed
14 Nov 2023
latest of these filings; the earliest 14 Nov 2023
Managers listing it
3
at least, of 95 tracked, among listed positions
Comparable managers
93
filed both Q2 2023 and Q3 2023; 2 listed it in both
Shares listed
10,916,011
combined, among listed positions
Reported value
$385m
combined, at the quarter end

Managers listing GMAB in Q3 2023

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q2 2023, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

3 of 3 holders

ActionFiling
AllianceBernstein LP9,515,209$336m0.14%Added+1,327,63314 Nov 2023 (the filing on sec.gov)
Renaissance Technologies LLC1,174,000$41m0.07%Added+334,90014 Nov 2023 (the filing on sec.gov)
Schonfeld Strategic Advisors LLC226,802$8.0m0.06%Newnew14 Nov 2023 (the filing on sec.gov)

Largest increases and reductions, by shares

Q2 2023 to Q3 2023, among managers that listed it in both quarters or opened it.

Increases

Reductions

No reduction among listed positions.

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (1)

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
6 in Q3 2024 to 7 in Q2 2026

Tracked managers listing it, at least.

0358102020202120222023202420252026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
GMAB by quarter
QuarterHoldersReported valueBuyersSellers
Q3 20193$95mn.a.n.a.
Q4 20193$99mn.a.n.a.
Q1 20205$114mn.a.n.a.
Q2 20206$224mn.a.n.a.
Q3 20207$364mn.a.n.a.
Q4 20205$238mn.a.n.a.
Q1 20213$121mn.a.n.a.
Q2 20213$187mn.a.n.a.
Q3 20213$166mn.a.n.a.
Q4 20213$168mn.a.n.a.
Q1 20224$168mn.a.n.a.
Q2 20224$96mn.a.n.a.
Q3 20227$412mn.a.n.a.
Q4 20226$422mn.a.n.a.
Q1 20233$333mn.a.n.a.
Q2 20232$343mn.a.n.a.
Q3 20233$385mn.a.n.a.
Q4 20234$548m40
Q1 20246$540m24
Q2 20246$457m51
Q3 20246$447m31
Q4 20248$480m61
Q1 20258$495m61
Q2 202510$495m37
Q3 20257$643m35
Q4 20255$617m810
Q1 20266$623m1112
Q2 20267$583m156

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

GMAB and LLY →GMAB and JNJ →GMAB and VRTX →Choose a stock to compare with GMAB →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own GMAB, latest filings →Back to the 13F Explorer →